Strategic Leadership Recent leadership transition to Joanne Kotz as CEO suggests a potential shift in strategic priorities and funding approaches. This may present an opportunity to engage on long-term partnerships, collaboration models, and non-dilutive funding discussions aligned with new executive vision.

Pipeline Progress Wholly owned CNS RNAi pipeline plus a Genentech partnership indicate active development and upcoming clinical milestones. Target opportunities include advisory roles, CRO/CMC partnerships, and early access discussions for potential co-development or licensing aligned with near-term program milestones.

Financing Momentum Significant Series B funding underscoring investor confidence and runway for expansion. Sales opportunities exist in strategic collaborations, value-adding partnerships, and platform licensing that can accelerate preclinical-to-clinical transitions or broaden the pipeline through co-funding arrangements.

Neurological Focus Specialization in Huntington’s disease, genetic epilepsy, severe chronic pain, and other CNS disorders positions the company for companion diagnostics, biomarker development, and CNS delivery optimization services, as well as potential reimbursement strategy collaborations with pharma partners.

Geographic and Talent Footprint Boston-based operations with a lean team indicate potential leverage for local partnerships, clinical trial site collaborations, and specialized CRO/academic collaborations. Opportunities may include regional business development efforts and talent-driven partnerships for specialized manufacturing or regulatory affairs support.